Announcement of resignation of the Chairperson

OBI licensed the worldwide therapeutic rights of OBI-858 to OBIGEN

Announcement on behalf of subsidiary, OBIGEN, that the Company’s board appointed internal audit officer

OBI has filed the application of Phase I/II human clinical trial for OBI-992 TROP2 ADC to US FDA

OBI is invited to attend the investor conference hosted by MasterLink Securities and declare the development of all its products and future plan

The change of the Company's business address was approved by the Board of Directors

Announcement of change of internal audit officer

Announcement of change of financial officer

Announcement of the Consolidated Financial Statements for the third quarter of 2023 were approved by the Board of Directors

Announcement on behalf of Amaran that the institutional director changes its representative